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Abstract.  We report that a E1 integrin (o~5fll) can 
exist in different affinity states for its soluble ligand, 
fibronectin. The ot5fll  expressed by the erythroleu- 
kemic cell line K562 binds soluble fibronectin with 
low affinity (Ka >  1 #M), but is induced to bind it 
with 20-fold higher affinity (Kd-54 nM) in the presence 
of the anti-ill mAb 8A2.  This activation seems to be 
due to direct antibody-induced change in the receptor 
that does not require intracellular signaling, and is a 
plausible basis for the 8A2-induced enhancement of 
ill-dependent adhesion to fibronectin and other im- 
mobilized ligands (Kovach, N.  L., T. M.  Carlos, 
E. Yee, and J.  M.  Harlan.  1992.  J.  Cell BioL  116: 
499-509).  Fab fragments of 8A2 bind with higher 
affinity to ot5fll receptor that is occupied by the GRG- 
DSP peptide ligand suggesting that the antibody func- 
tions by stabilizing a high affinity (occupied) conformer 
of the receptor. A functional consequence of the 
affinity modulation is that soluble fibronectin (at physi- 
ological concentrations) occupies the high affinity re- 
ceptors, and so becomes an effective inhibitor of ad- 
hesion to immobilized fibronectin. In contrast, the 
majority of low affinity receptors remain unoccupied 
and are still  able to mediate cellular adhesion. 
C 
eLL adhesion is controlled by interactions between ad- 
hesion receptors and  their ligands.  Changing  the 
repertoire of  adhesive receptors, by either modifying 
biosynthetic patterns (16, 39, 45, 47) or by receptor translo- 
cations (8, 35), are strategies to modify cell adhesion.  The 
function of adhesion receptors can also be changed by struc- 
tural alterations,  by changes in mRNA splicing (5,  10, 30, 
41, 54), proteolytic cleavage (31), or variations in glycosyla- 
tion (17). Finally, cellular adhesion can be rapidly regulated 
through reversible modulation of receptor function, and this 
mechanism is a key feature of  the integrin family of  adhesion 
receptors (4,  15, 42, 51, 52). 
The most widespread integrins are the/31 subfamily (VLA 
family) (27-29),  and there is dynamic regulation of fll inte- 
grin-mediated adhesion.  T  lymphocytes and T  lymphoid 
cell lines,  activated  either with phorbol esters,  by cross- 
linking CD3, or with activating combinations  of anti-CD2 
mAbs, exhibit increased ill-dependent adhesion to immobi- 
lized ligands (51, 52). This occurs without alterations in their 
repertoire of integrins.  Cellular adhesion to immobilized 
ligand  is  a  complex multi-step  process,  involving  initial 
receptor-ligand interaction,  followed by strengthening  of 
adhesion  through organization  of the cytoskeleton, focal 
contact formation, and cell spreading (11, 55).  Cells could 
enhance adhesion by the facilitation of  any of  these steps. For 
example,  Danilov et al.  (14) found that phorbol esters en- 
hanced the adhesion of CHO cells to immobilized fibronec- 
tin  without any detectable change in the affinity of their 
fibronectin receptors for soluble ligand.  Alternatively,  the 
ligand binding affinity of certain integrins can be rapidly al- 
tered. For example, platelet receptor allbfl3 (or GPIIbHIa) 
exists in at least two affinity states  for its soluble ligand, 
fibrinogen (7, 33, 50), which appear to be a result of  different 
conformations of the receptor (13, 40). Conversion from low 
to high affinity binding of fibrinogen can be induced by treat- 
ing the platelets with agonists such as phorbol esters, ADP, 
and thrombin (43, 44), and by certain mAbs directed against 
the f13 chain (40).  Interconversion  between low and high 
affinity fihrinogen binding states also occurs with otMff2  (4). 
Direct demonstration of affinity modulation of fll integrins 
has not been reported. However, it is known that soluble 
fibronectin binds with moderate affinity to E1 integrins ex- 
pressed by cell lines such as CliO cells (K~ =  100 nM) (14) 
and BHK cells (Kd =  800 riM) (1). 
Several anti-B1 mABs which enhance/31 integrin-depen- 
dent cellular adhesion have been described (6, 32, 38, 53). 
In this paper we have used one of these antibodies (8A2, ref- 
erence 32), to investigate affinity modulation of  the fibronec- 
tin receptor, ot5fll. We show that the a5fll expressed by the 
erythroleukemic cell line K562  binds  soluble  fibronectin 
with low affinity which can be increased 20-fold by 8A2. The 
alteration in affinity occurs in the presence of inhibitors  of 
intracellular signaling, and it appears that the antibody func- 
tions by directly inducing a high affinity conformation of the 
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ulation of a5B1 were found to depend on the ambient soluble 
fibronectin concentration. 
Materials and Methods 
Antibodies and Reagents 
Production and initial characterization of the murine anti-human/31 mAb 
8A2 (IgGl-r isotype) has been described (32). The rat anti-human ~5 mAb 
BIIG2 and rat anti-human/~1 mAb AIIB2 (23) were used as dilutions of 
ascites. The murine anti-human a4 mAb HP2/1  (49) was used as dilutions 
of tissue culture supernatant. The murine anti-human/~1 mAbs AlAS and 
TS2/16  (25)  were used as dilutions of ascites.  The murine anti-human 
fibronectin mAb Fnl.ll was produced in our laboratory as described (9), 
and used as dilutions of ascites. The murine anti-human HLA class I mAb 
W6/32  was obtained from the American Type Culture Collection (Rock- 
ville, MD) and used as dilutions of purified IgG. The peptide GRGDSP was 
obtained  from  Peninsula  Laboratories  (Belmont,  CA)  and  the  peptide 
GRGESP was synthesized in the Scripps Research Institute core facility (La 
Jolla, CA). Glucose and 2-deoxyglucose were purchased from Sigma (St. 
Louis, MO) and sodium azide from Fisher Scientific Co. (Pittsburgh, PA). 
Cells 
The erythroleukemic cell line K562 was obtained from the ATCC, and was 
maintained  in  RPMI  medium  (Biowhittaker,  Walkersville,  MD)  sup- 
plemented with 10% FCS (Biowhittaker), 1% glntamine (Sigma), and 1% 
penicillin and 1% streptomycin (Sigma). U937, Jurkat (both from ATCC), 
and Molt-13  (from Dr. Dario Altieri, The Scripps Research Institute) cells 
were maintained in the same medium. THP-1 cells (from the ATCC) were 
maintained in this medium with the addition of 10 mM Hepes and 20 mM 
2-mercaptoethanol. Human T lymphocytes were purified from the periph- 
eral blood of normal donors by centrifugation on a Ficoll-Paque gradient 
(Pharmacia Fine Chemical, Piscataway,  N J),  panning for monocytes on 
serum-coated dishes, and passaging over a nylon wool column. 
Purification of SA2 IgG and Fab Fragments 
8A2 whole IgG was purified from ascites by binding to protein A immobi- 
lized on sepharose beads (Pharmacia LKB, Uppsala, Sweden). The anti- 
body was incubated with the protein A-sepharose under high salt conditions 
(3.3 M NaCI and 0.5 M Na borate, pH 8.9), and eluted with 100 mM gly- 
cine, pH 3.0 into tubes containing L0 M Tris, pH 8.0. The peak fractions 
were pooled and dialyzed overnight against PBS. Fab fragments were pro- 
duced by overnight incubation of the purified 8A2 IgG with papain cross- 
linked to beaded agarose (Pierce Chemical Co., Rockford, IL), according 
to the manufacturer's instructions. After removal of the immobilized papain 
by centrifugation, the supernatant was passed over a protein A-sepharose 
column, and the non-binding fraction analyzed for purity of the Fab frag- 
ments by SDS-PAGE under non-reducing conditions. Densitometry con- 
firmed that <2% of the 8A2 Fab preparation remained in the form of intact 
IgG. The concentration of purified IgG and Fab fragments was determined 
by absorbance at 280 nm (1  OD  =  0.8 mg/mi) (24). 
Purification of  Human Fibronectin 
Fibronectin was isolated from fresh human citrated plasma by affinity chro- 
matography on gelatin-sephamse (Pharmacia Fine Chemical), as we have 
previously described (42). The isolated fibronectin yielded a single band on 
SDS-PAGE under non-reducing conditions, and a closely spaced doublet of 
215,000  and 230000  D  under reducing conditions, consistent with the 
reported properties of plasma fibronectin (12). The concentration of fibro- 
nectin was determined by absorbance at 280 nM v~0.1~A2s°m  =  1.3) (36). 
Radiolabeling of  Fibronectin and 8A2 Fab Fragments 
The fibronectin was labeled with 125Iodine by a  modified Chloramine-T 
procedure, as described (42). The 8A2 Fab fragments were radiolabeled by 
the same Chloramine-T method, the sample run over a  PDI0 Sephadex 
column  (Pharmacia  Fine  Chemicals),  and  the  peak  activity  fractions 
pooled. Greater than 90%  of the radioactivity was precipitated by  10% 
TCA.  Aliquots were stored at -70°C following the addition of BSA to 1% 
final  concentration. 
Binding Assays 
Assays of the binding of ~2SI-labeled fibronectin and 8A2  Fab fragments 
were based on assays of fibronectin binding to platelets that we have previ- 
ously described (42). The standard buffer used in the assays was modified 
Tyrode's buffer (150 mM NaCI, 2.5 mM KC1, 12 mM NaHCO3,  1 mg/ml 
BSA,  1 mg/ml glucose, and 2  mM MgC12), pH 7.4.  Cells were washed 
twice in the appropriate buffer before being suspended in the same at the 
indicated density. The incubation time was typically 30 min at room temper- 
ature, as pilot studies showed that >90 % of  the maximal fibronectin binding 
occurred by this time.  A  typical binding assay,  performed in a  1.5-mi 
microcentrifuge tube (Sarstedt, Germany), was in a 200-/~1 vol composed 
of  120  /~1  of cells (2  x  l0  s  per tube),  40  /~1  of radiolabcled  protein 
(fibroncctin or 8A2), and 40/~1 of stimulus (e.g., cold 8A2) and/or inhibitor 
(e.g., EDTA, mAb, GRGDSP). After the incubation, 50-#1 aliquots were 
layered in triplicate onto 300  Izl of 20%  sucrose in the same buffer in 
microfuge tubes  (West Coast  Scientific Inc.,  Hayward,  CA),  and  cen- 
trifuged for 3 min at  12,000 rpm in a microfuge (Beckman Instruments, 
Fullerton, CA). The tips were amputated and counted, and the bound pro- 
tein was calculated from the specific activity of the ligand (assuming a mo- 
lecular weight offibronectin  as 440,000 and 8A2 Fab fragments  as 50000 D). 
For fibronectin binding, the residual bound radioactivity in the presence of 
5  mM EDTA was subtracted as non-specific binding (i.e., non-integrin- 
dependent binding). The bound fibronectin did not undergo detectable pm- 
teolytic  degradation  or  transglutaminase-mediated cross-linking during 
these experiments, as the bound fibronectin subunits showed identical mo- 
bility to input subunlts on reduced SDS gels. Reversibility of the fibronectin 
binding was established in control experiments where EDTA was added to 
the mixture of cells and radiolabeled fibronectin 30 min after the com- 
mencement  of  the incubation. Greater than 90 % of  the radiolabel was eluted 
from the cells after 90 rain of incubation with the EDTA. For 8A2 Fab frag- 
ments, the non-specific binding was determined in the presence of a 50x 
excess of cold 8A2 IgG. The data was fitted to equilibrium binding models 
using the LIGAND program (37). 
Assays of Cell Adhesion to Immobilized Fibronectin 
The assay of K562 adhesion to immobilized fibronectin were based on that 
described by Prater et al. (46). Fibronectin was diluted in PBS, pH 7.4, and 
50-/~1 aliquots incubated in the wells of a 96-well Immulon H plate (Dy- 
natech Laboratories Inc., Chantilly, VA) for 2 h at 37°C. After washing with 
PBS, the wells were blocked with 1% BSA in PBS for 1 h at 37"C. The 
buffer used in the adhesion assay was the same as in the binding assays. Cells 
were washed twice in this buffer, resuspended at  1  x  106 cells/ml, and 
100-/~1 aliquots added to the emptied wells. Where required, appropriate 
concentrations of stimulus or inhibitor (e.g., antibody EDTA) were mixed 
with the cells when they were added to the wells, except in assays involving 
soluble fibronectin. In this case, the cells were preincubated with antibody 
(8A2 or W6/32) and soluble fibronectin for 30 min rocking at room tempera- 
ture, before addition to the wells. After a 30-rain incubation at room temper- 
ature, the non-adherent cells were washed off with three rounds of gentle 
pipetting. The residual adherent cells were checked by visual inspection, 
and quantified with a colorimetric reaction using endogenous cellular acid 
phosphatase activity by adding 100 #1 of the following substrate/lysis solu- 
tion to each well: 1% Triton X-100 (Fisher Scientific Co.), 6 mg/ml p-nitro- 
phenylphosphate (Sigma), in 50 mM sodium acetate buffer,  pH 5.0. After 
a  1-h incubation at 37°C, the reaction was terminated by the addition of 
50/~1 of 1 M NaOH, and read in an ELISA plate reader (Molecular Devices 
Corp., Menlo Park, CA) with a 410 nm filter.  Background values, deter- 
mined in wells coated with 1% BSA alone, were subtracted from each point. 
Adherence was expressed as a percentage of the number of cells originally 
added to each well, and determined from a standard curve generated using 
known numbers of cells. 
Results 
~5~ I on Nonadherent Cells Binds Little 
Soluble Fibronectin 
As noted in the introduction, at least two adherent cell lines 
(1,  14)  express  t~5/31 that binds  soluble  fibronectin  with 
moderate affinity. To investigate the affinity state of ct5~l on 
cells that grow in suspension, we assessed fibronectin bind- 
ing to the K562 erythroleukemic cell line. These cells were 
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t25I-labeled fibronectin  (100 nM) was added to 2  x  106 K562 cells 
in a final volume of 200 #1. After incubation at 22°C for 30 rain, 
bound  fibronectin  was  assayed  as  described  in  Materials  and 
Methods. The added reagents were: 8A2 (anti-/31; reference 32) (20 
nM purified IgG), BIIG2 (anti-c~5; reference 23) (1:200 dilution of 
ascites),  FnI-11 (anti-cell  binding domain of fibronectin;  reference 
9) (1:50 dilution of ascites),  HP2/I (anti-cx4; reference 49) (1:10 di- 
lution of culture supernatant),  and peptides  GRGDSP and GRG- 
ESP (250 ~,M). Results are the mean +  SD of  three determinations. 
chosen because they express only o~5fll of the 81 integrins, 
and do not express/93  integrins without induction (26).  In 
contrast to BHK or CHO cells (1,  14), very little binding of 
soluble fibronectin to the K562 cells was observed (Fig.  1). 
Nevertheless,  the cx5/~l on these cells had the potential  to 
bind  substantial  soluble  fibronectin in the presence  of the 
monoclonal  antibody  8A2.  The  8A2-induced binding  was 
completely inhibited by a blocking antibody against the or5 
chain (Fig.  1), confirming that a5fll  was responsible for all 
the  observed  binding.  Moreover,  it  was  mediated  by  the 
"classical" cell binding site in fibronectin, as it was blocked 
by  a  monoclonal anti-fibronectin  antibody that  recognizes 
this site (9), and by an RGD- but not an RGE-containing pep- 
tide (Fig.  1).  Consistent with integrin-mediated binding,  it 
Table I. 8A2 Induces the Binding of  Soluble Fibronectin 
to Purified Peripheral Blood T Lymphocytes 
Fibronectin bound 
[8A2 IgG] nM  (molecules per cell) 
0.0  1,515  +  748 
0.2  2,040 +  628 
2.0  4,505  +  960 
20  5,515  +  1,534 
Peripheral blood T  lymphocytes were isolated from heparinized venous blood 
of volunteer donors by centrifugation on a  Ficoll-Paque gradient, panning on 
serum-coated dishes to  remove monocytes,  and  passage over a  nylon wool 
column.  ~#I-labeled soluble fibronectin (200 nM) was incubated with 2  x  10  ~ 
T lymphocytes in a final volume of 200/~1 in the presence of increasing concen- 
trations of 8A2  whole  IgG.  After  incubation at  22°C  for  30  rain,  bound 
fibronectin was assayed as described in Materials and Methods. Results are ex- 
pressed as mean  +  SD of three determinations. 
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Figure 2.  The binding of soluble  fibmnectin to K562 cells  is in- 
duced by both 8A2 whole IgG and Fab fragments.  Purified 8A2 IgG 
and  monovalent  Fab  fragments  were produced  as  described  in 
Materials  and Methods.  Increasing concentrations of each were 
added to 2  x  10  ~ K562 cells in a final volume of 200 ~1. After in- 
cubation at 22°C for 30 rain,  bound fibronectin  was assayed as de- 
scribed in Materials  and Methods. 
failed to occur in buffer depleted of divalent cations or in the 
presence of  EDTA (data not shown). The lack of  high affinity 
fibronectin binding to o~5~l appears to be a general property 
of non-adherent hematopoietic cell lines,  as similar results 
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Figure 3.  Specific binding of increasing  concentrations of soluble 
fibronectin  to K562 cells,  either in the presence (H)  or ab- 
sence (o---o) of 20 nM of 8A2 whole IgG. Soluble  ~25I-labeled 
fibronectin  of known concentration was added to 2  x  10  ~ K562 
cells in a final volume of 200 ~,1. After incubation at 22°C for 30 
rain,  bound fibronectin  was assayed as described in Materials  and 
Methods. Nonspecific binding was estimated  from the amount of 
fibronectin  bound in the presence of 5 mM EDTA. 
Faull et al. Affinity Modulation  of Integrin  ¢~5/31  157 120~00 
~"  100900- 
_= 
j 
O 
E 
-o  60,000 
C  -i 
.8 
¢:  40,000 
..g_  20,000 
IJ. 
0  0.2  2  20 
E 
@ 
@  ¢., 
w 
@ 
0 
40 
30 
20 
10 
0  .2  2  2; 
[8A2]  (nM)  [8A2]  nM 
Figure 4. The metabolic inhibitors sodium azide and 2-deoxyglucose inhibit the adhesion of K562 cells to immobilized fibronectin, but 
have no effect on the 8A2-enhanced binding of soluble fibronectin to K562 cells nor on the 8A2-enhanced adhesion of K562 cells to immobi- 
lized fibronectin. (a) Binding of ~25I-labeled soluble fibmnectin to K562 cells was determined in the presence of increasing concentrations 
of 8A2 whole IgG, as described in Materials and Methods. Before the binding assay, the cells were incubated for 30 min at 37°C in either 
the standard modified Tyrode's buffer, or in buffer with the glucose replaced by sodium azide (0.1%) and 2-deoxyglucose (5 raM), and 
the binding assay performed in the same buffer. Results are the mean +  SD of three determinations.  (b) The adhesion of K562 cells to 
immobilized fibmnectin was determined as described in Materials and Methods. Fibronectin (0.5 #g/well) was coated onto plastic micro- 
titer wells for 2 h at 37°C. Cells were preincubated in either buffer as above, and the 30 min adhesion step performed in triplicate wells 
at 220C in the presence of increasing concentrations of 8A2 whole IgG. Percent adherence was determined and results expressed as mean 
:i:  SD of three determinations.  (-6y-) Standard buffers; (+)  metabolic inhibitor. 
were  obtained  with  the  monocytic  cell  lines  THP-1  and 
U937, and the lymphoid cell lines Jurkat and Molt-13 (data 
not  shown).  In addition,  peripheral blood T  lymphocytes 
also manifested little basal fibronectin binding,  and an in- 
creased in the presence of 8A2 (Table I). 
The binding of fibronectin to K562 cells in response to 
varying concentrations of 8A2 has been quantified (Fig. 2). 
Fibronectin binding approached saturation at above 4 nM of 
8A2  IgG, and the EC50  was  ,ol.0 riM.  Specificity of this 
effect was documented by the failure of another anti-/31 mAb 
(AIIB2, reference 23) or an irrelevant antibody (W6/32- anti- 
HLA  class  I)  to  induce  this  response  (data  not  shown). 
Moreover,  purified  Fab  fragments of 8A2  were  also  able 
to  induce  fibronectin  binding  (Fig.  2),  albeit  with  lower 
efficiency than intact IgG. The contaminating whole IgG in 
the Fab preparation could account for <10% of this activity. 
Thus, the 8A2 effect was not dependent on bivalency nor on 
the Fc portion of the antibody molecule. 
In additional  experiments,  the mAbs A1A5  and TS2/16, 
which also stimulate cellular adhesion to immobilized ex- 
tracellular matrix proteins (6,  53), were able to induce the 
binding  of soluble  fibronectin  to  K562  cells  (results  not 
shown). 
AJfinity Modulation of c~5~  l 
To characterize the mechanism of the increase in fibronectin 
binding induced by 8A2, detailed equilibrium binding iso- 
therms were analyzed. In the absence of 8A2 there was little 
binding of fibronectin, although at higher fibronectin con- 
centrations  some specific binding  was  observed (Fig.  3). 
This data could be fitted to a single site binding model with 
an estimated affinity, Ka, =  8.6 (+3.4)  x  llY M -t (K~ -- 1.2 
#M),  and receptor concentration of 1.5  (+0.5)  nM (9.0  x 
104 receptors/cell). In the presence of 20 nM of 8A2 IgG, 
fibronectin bound with an estimated Ka of 1.8 (4-0.3)  ×  107 
M -t  (Ka  =  54  riM),  and  receptor  concentration  of  3.3 
(+0.3)  x  107 M -t (Ka =  54 nM),  and receptor concentra- 
tion of 3.3 (4-0.25) nM (19.9  x  1@ receptors/cell) (Fig. 3). 
The 20-fold difference in receptor affinity observed in the 
presence of 8A2 was highly significant by constrained pa- 
rameter (37) curve fitting (F =  63.4, df =  21, P <  0.0001). 
In sharp contrast, the twofold difference in estimated recep- 
tor number was not significant (F =  1.7, df =  21, P  =  0.22). 
Thus, the 8A2 antibody changes the binding affinity of ot5/31 
for fibronectin, and/31  integrins,  like/32 and/33  integrins, 
can undergo affinity modulation. 
Mechanism of  Afflnity Modulation by &42 
Active cellular responses have been implicated in the capac- 
ivy of anti-~'l monoclonal antibodies to promote cell adhe- 
sion (6, 32, 53), suggesting that these antibodies might work 
by activating intracellular  signaling  systems.  However,  in 
sharp contrast to previous results, the 8A2-induced increase 
in fibronectin binding was not affected by the metabolic in- 
hibitors sodium azide and 2-deoxyglucose (Fig.  4 a).  The 
effect of these drugs on the K562 cells was documented in 
concurrent measurements of cellular adhesion to immobi- 
lized fibronectin (Fig. 4  b).  The metabolic inhibitors pro- 
foundly suppressed basal adhesion to fibronectin. Neverthe- 
less,  8A2  promoted  similar  increases  in  adhesion  in  the 
presence of absence of the inhibitors. Thus, the combination 
of the inhibitors suppressed a5/31-dependent cellular adbe- 
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Figure 5.  The number of fibronectin molecules bound per cell 
directly correlates with the number of 8A2 molecules bound. Paral- 
lel binding assays were performed as described in Materials and 
Methods. A fixed concentration of  radiolabeled fibronectin (50 riM) 
was incubated with 2 x  10  ~ K562 cells for 30 min at 22°C in the 
presence of increasing concentrations of unlabeled 8A2 lab frag- 
ments. The number of fibronectin molecules bound per cell was 
determined at each concentration of 8A2 Fab. In parallel, the num- 
ber of 125I-labeled 8A2 Fab fragments bound per cell in the pres- 
ence of the same concentration (50 nM) of unlabeled fibronectin 
was determined for the same concentrations of 8A2 Fab. 
sion  to  fibronectin  without  affecting  the  affinity  of the 
fibronectin-integrin interaction.  In  addition,  treating  the 
cells with 0.02 #g/ml of cytochalasin D did not reduce 8A2- 
induced fibronectin  binding even though it effectively  blocked 
basal  cell  adhesion  to  immobilized  fibronectin (data  not 
shown). 
We also examined the relationship between the binding of 
8A2 and fibronectin to K562 cells. To do this we simultane- 
ously measured the binding to K562 cells of 50 nM of radio- 
labeled fibronectin and varying doses of radiolabeled 8A2 
Fab fragments. As the concentration of 8A2 Fab increased, 
the binding of 8A2 Fab fragments (cf. Fig. 6 b) and fibronec- 
tin (cf. Fig. 2) approached saturation. Replotting of this data 
as 8A2 bound versus fibronectin bound showed a remarkable 
correlation between the number of 8A2 molecules bound and 
the number of high affinity (~5/31 fibronectin receptors, i.e., 
the number of fibronectin molecules bound (r =  0.995) (Fig. 
5). This suggests that only those 0t5/31 molecules that have 
physically associated with 8A2 bind fibronectin with high 
affinity. 
Taken together, the lack of energy requirement and direct 
nature of the effect of 8A2 suggests that it binds ot5/31 and 
directly  promotes  an  increase  in  ligand  binding  affinity 
through a change in receptor conformation. To determine 
whether 8A2 also preferentially recognizes an occupied con- 
former of a5/31,  the binding of 8A2 Fab fragments to K562 
cells  was  quantitated  in  the  presence or  absence  of the 
GRGDSP peptide ligand. The addition of increasing concen- 
trations of GRGDSP resulted in a progressive increase in the 
binding of 10 nM 8A2 Fabs (Fig. 6 a). The EC50 for this 
effect was 7.0 #M,  which is similar to the IC50 we deter- 
mined for the inhibition of 8A2-induced fibronectin binding 
to K562 cells (5.5 #M, data not shown). To define the basis 
for this effect, the binding of 8A2 Fab fragments to K562 
cells in the presence or absence of 200 #M GRGDSP was 
analyzed (Fig. 6 b). In the presence of GRGDSP there was 
an approximate twofold increase in the affinity of 8A2 bind- 
ing (Ka =  5.5 [+ 0.7]  x  107 M -1 to ga =  10.5 [-I-2.0] x  107 
M-l), which was statistically significant (F =  6.8, df =  28, 
P  =  0.015).  In contrast, the receptor concentration (3.1 to 
3.0 nM) was not significantly different in the presence of the 
peptide (F =  0.2, df =  28, P  =  0.65). Thus, ligand binding 
to the ot5~l increases the affinity of 8A2 binding. 
Binding Affinity Governs the Inhibition of CeUular 
Adhesion by Soluble l~bronectin 
Although soluble fibronectin and fibronectin fragments in- 
hibit the adhesion of some cells to immobilized fibronectin 
(2, 56), other workers have failed to observe this dualistic 
role for fibronectin (22). We examined the possibility that 
affinity modulation of ot5/31 alters the capacity of soluble 
fibronectin to  block  cell  adhesion.  K562  cells  were  in- 
cubated with either an irrelevant antibody (W6/32) or 100 
nM of8A2 IgG in the presence or absence of 675 nM of solu- 
ble  fibronectin,  and  permitted to  adhere  to  immobilized 
fibronectin. Soluble fibronectin modestly (•50  %) inhibited 
the low basal adhesion of K562 cells (Fig. 7). As expected, 
8A2  nearly  tripled  adhesion  to  immobilized  fibronectin. 
Strikingly,  the  addition  of physiological plasma  levels of 
soluble fibronectin (450-900 nM; 1, 36), in the presence of 
8A2, completely suppressed specific adhesion to fibronec- 
tin. In the presence of soluble fibronectin, the net effect of 
the 8A2 antibody was profound inhibition of cell adhesion. 
Thus, the functional consequences of affinity modulation of 
a5/31 are influenced by the ambient concentration of soluble 
fibronectin. 
Discussion 
The most important findings in this work are: (a) a/31 inte- 
grin (ot5/31) can exist in different affinity states; (b) the anti- 
~1  mAb  8A2  stimulates  cell  adhesion by  converting the 
receptor from a low to a high affinity state; (c) this activation 
seems to be due to antibody-induced change in the receptor 
without intracellular signaling; and (d) the functional conse- 
quences of affinity modulation of the ot5/31 integrin depend 
on the ambient soluble fibronectin concentration. 
The a5/31  integrin  can  manifest differing affinities for 
soluble fibronectin. The K562 cells (as well as the other non- 
adherent cell lines that we tested) bind soluble fibronectin 
with low affinity (Kd >  1 #M), but can be induced to bind 
it with 20-fold higher affinity (Kd =  54 riM). It is noteworthy 
that the fibronectin receptors on the adherent CHO and BHK 
cell lines have a measured affinity for soluble fibronectin that 
lies between these two values (1, 14), implying that multiple 
affinity states exist. We have also found that soluble fibro- 
nectin binds to CHO cells with a similar affinity to that previ- 
ously reported (Kd =  95 nM vs. 100 nM reported reference 
14) (results not shown). This suggests that at plasma concen- 
trations of fibronectin, high affinity receptors on adherent 
cells (e.g., fibroblasts) will be fully occupied. In contrast, 
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Figure 6.  8A2 Fab fragments bind with higher affinity to K562 cells in the presence of the GRGDSP peptide ligand. (a) 125I-labeled 8A2 
Fab fragments (10 nM) were incubated with 2  x  106 K562 cells in a final volume of 200/d in the presence of increasing concentrations 
of GRGDSP (0 to 500/~M). After incubation at 22°C for 30 min, bound 8A2 was assayed as described in Materials and Methods. Results 
are the mean + SD of three determinations.  (b) Known concentrations |~I-labeled 8A2 Fab fragments were incubated with 2  ×  10  ~ K562 
cells in a final volume of 200 #1 in the absence or presence of a fixed concentration of GRGDSP peptide (200/~M).  After incubation at 
22"C for 30 rain, bound 8A2 was assayed as described  in Materials  and Methods. Nonspecific binding was determined  in the presence 
of a 50x  excess of unlabeled 8A2, and results are expressed as the estimated specific binding.  (e) GRGDSP;  (o) no addition. 
low affinity ct5/~l on non-adherent cells (e.g., circulating T 
lymphocytes) would be expected to have much lower frac- 
tional occupancies. 
The anti-/~l mAb 8A2 induces the K562 cells to bind solu- 
W6/32  alone  8A2 alone  W6/32  +sFn  8A2+aFn 
Figure  7. Soluble fibronectin (sFn) more effectively inhibits K562 
cell adhesion to immobilized fibroneetin in the presence  of 8A2. 
K562 cells were preincubated in buffer for 30 rain at 22"C with 100 
nM of the irrelevant monoelonal antibody W6/32 or of 862, and 
with or without 675 nM of soluble fibroneetin. Cellular adhesion 
to fibronectin (0.5 #g/well)  immobilized on rnicrotiter wells was 
performed in triplicate as described in Materials and Methods. Per- 
cent adherence was determined and results expressed as mean + 
SD of three determinations. 
ble fibronectin with higher affinity, which is a plausible basis 
for antibody enhancement of cellular adhesion to immobi- 
lized  fibronectin.  It is  likely that  the  capacity of 8A2  to 
stimulate adhesion via other/31 integrins (32) is by the same 
mechanism.  The  8A2-induced  fibronectin binding  has the 
appropriate characteristics  for  an  integrin-ligand  interac- 
tion, in that it is inhibited by the appropriate blocking anti- 
bodies as well as GRGDSP, and is dependent on the presence 
of divalent cations. 
The 8A2-induced increase in receptor affinity is due to a 
direct effect on the receptor that is apparently independent 
of intracellular signaling. We found that the increased bind- 
ing  of  soluble  fibronectin  in  the  presence  of  8A2  was 
unaffected by treating the cells with the metabolic inhibitors 
sodium  azide  and  2-deoxyglucose,  even though  the  same 
treatment effectively inhibited the adhesion of these cells to 
immobilized fibronectin. In addition, the metabolically "poi- 
soned" cells still had enhanced adhesion in the presence of 
increasing concentrations of 8A2. This suggests that directly 
increasing receptor affinity for its ligand will by itself pro- 
duce a  measurable increase in adhesion,  but that maximal 
adhesion requires the participation of further events that are 
dependent on the generation of intracellular ATE e.g., cyto- 
skeletal  organization,  focal  contact  formation,  and  cell 
spreading (11, 55). The fight correlation between fibronectin 
and  8A2  binding  to  the  cells  also  suggests  that  the  high 
affinity binding state of each receptor is directly dependent 
on an attached 8A2 molecule. Since the 8A2 Fab fragments 
bind with higher affinity to receptor that is occupied by the 
GRGDSP peptide ligand, the antibody may stabilize a high 
affinity (occupied)  conformer of the  receptor.  Several ac- 
tivating anti-/33  mAbs also bind with higher affinity to the 
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(ligand-induced binding sites) (19-21, 40).  Thus it may be 
that many  activating  anti-integrin  antibodies are  also anti- 
LIBS. 
The functional consequences of affinity modulation of the 
c~5fll receptors depends on the ambient soluble fibronectin 
concentration.  At  physiological  plasma  concentrations  of 
soluble fibronectin, a minority of the low affinity fibronectin 
receptors expressed by a cell will be occupied. In contrast, 
at the same concentration of fibronectin virtually all of the 
high affinity receptors will be occupied. For example, at the 
soluble fibronectin concentration of 675 nM that is used in 
the experiments summarized in Fig. 7, the calculated frac- 
tional  occupancy  of  the  low  affinity  receptors  is  36%, 
whereas the fractional occupancy of the high affinity recep- 
tors is calculated to be 93 %. Therefore, in the presence of 
saturating  concentrations  of 8A2,  soluble  fibronectin  be- 
comes a potent inhibitor of cellular adhesion to immobilized 
fibronectin by binding  to the high affinity  receptors.  This 
"dualistic  role" for fibronectin has  been  observed  in cells 
which express moderate affinity  fibronectin receptors (56). 
Hence, circulating leukocytes expressing low affinity recep- 
tors will retain their capacity  to adherent  to immobilized 
fibronectin that is laid down at sites of injury  and during 
wound  healing.  In  contrast,  adherent  cells  express  high 
affinity fibronectin receptors which could serve to bind solu- 
ble fibronectin from solution. This may be central to the in- 
volvement of u5/~l in the assembly of an extracellular fibro- 
nectin matrix (3,  18, 34, 48). 
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